Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVZLIB)

Drug Name
AHL Drug Info
Synonyms AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
Indication
Disease Entry ICD 11 Status REF
Hearing disorder AB50-AB57 Investigative [1]
Cross-matching ID
TTD Drug ID
DMVZLIB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P53 messenger RNA (TP53 mRNA) TT12KOD P53_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
P53 messenger RNA (TP53 mRNA) DTT TP53 5.257 4.938 5.396 5.626
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hearing disorder
ICD Disease Classification AB50-AB57
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P53 messenger RNA (TP53 mRNA) DTT TP53 7.90E-07 0.3 0.59
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.